pioglitazone + gliclazide

Pioglitazone + gliclazide is an oral fixed-dose combination of two antidiabetic agents used in the management of type 2 diabetes mellitus. Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, muscle, and the liver. Gliclazide is a sulfonylurea that stimulates pancreatic beta cells to release insulin by inhibiting ATP-sensitive potassium channels on the cell membrane. The combination targets both insulin resistance and impaired insulin secretion, providing complementary mechanisms for glycemic control in adults with type 2 diabetes who are inadequately controlled on monotherapy or require dual therapy[1][3][4].